|
WO2020037012A1
|
|
Calpain-2 selective inhibitor compounds for treatment of glaucoma
|
|
WO2019232368A1
|
|
TARGETING P18 FOR mTOR-RELATED DISORDERS
|
|
WO2019113461A1
|
|
Lipid emulsified drug delivery systems for chemoprevention and treatment
|
|
WO2019104294A1
|
|
Fluorophore-labeled phosphorodiamidate morpholino oligonucleotides and uses thereof
|
|
WO2019006348A1
|
|
Factor ix-transferrin fusion proteins
|
|
US2019206273A1
|
|
Formative feedback system and method
|
|
TW201817416A
|
|
Formulations for treating bladder cancer
|
|
TW201811336A
|
|
Proliposomal testosterone undecanoate formulations
|
|
CR20180388A
|
|
FORMULATIONS FOR THE TREATMENT OF BLADDER CANCER
|
|
WO2017120592A1
|
|
Proliposomal testosterone undecanoate formulations
|
|
CN107206032A
|
|
Probiotic composition and application method
|
|
WO2016077461A2
|
|
Isoform-specific calpain inhibitors, methods of identification, and uses thereof
|
|
US2016199345A1
|
|
Use of wilforlide A for overcoming chemotherapy resistance
|
|
AU2013306058A1
|
|
Tripterygium wilfordii extracts to overcome chemotherapy resistance
|
|
KR20150032939A
|
|
Proliposomal testosterone formulations
|
|
AU2013259598A1
|
|
Standardized ex vivo platforms for the antigen-specific expansion of CD4+ T cell populations
|
|
US2013218546A1
|
|
Novel gtp cyclohydrolase type ib
|
|
EP2763658A1
|
|
Targeted liposomes in cancer therapy
|
|
AU2012200556A1
|
|
Coated drug delivery formulations
|
|
CN103228266A
|
|
Ternary mixture formulations
|
